WuXi Biologics: Net profit is expected to grow by 46.3% to 4.908 billion yuan in 2025, with significant growth in both the biopharmaceutical and XDC business segments.

On March 24, WuXi Biologics released its full-year results announcement for the year ended December 31, 2025. The company’s 2025 revenue was RMB 21.79 billion, up 16.7% year over year; gross profit was RMB 10.019 billion, up 30.9% year over year, with the gross margin rising to 46.0%; net profit attributable to shareholders was RMB 4.908 billion, up 46.3% year over year.

In the Management Discussion and Analysis section, the company mentioned that it drove significant business growth through an integrated CRDMO platform and its “follow and win with molecules” strategy. It added 209 comprehensive projects, bringing the total to 945. Late-stage clinical and commercial manufacturing projects also increased to 74 and 25, respectively.

In the notes to the financial statements, cost of sales increased from RMB 11.025 billion to RMB 11.772 billion, an increase of 6.8%. Overall, the company achieved significant growth in both of its two business segments—biologics and XDC. External sales for the biologics segment were RMB 15.89 billion, and external sales for XDC were RMB 5.9 billion, demonstrating the company’s strong performance and competitiveness in the market.

(WuXi Biologics announcement)

(Edited by: Yang Yan, Lin Chen)

Key words:

                                                            Medical